SEOUL, South Korea & CAMBRIDGE, Mass -Thursday 1 July 2021 [ AETOS Wire ]
LC350189 showed significant serum uric acid (sUA)-lowering effects across all dose levels.
LC350189 achieved a treatment target of sUA < 5 mg/dL as the primary endpoint at month 3 with all dose groups when compared with placebo, and Febuxostat.
LC350189 was shown to be well-tolerated.
(BUSINESS WIRE)-- LG Chem announced topline results for the phase 2 study evaluating the efficacy and safety profiles of LC350189, a novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.
LG Chem had received FDA clearance to commence a Phase 2 trial of LC350189 in June 2019 and conducted the Phase 2 study (CLUE study, NCT03934099) with 156 gout patients at 45 clinical sites in the US.
Participants with chronic gout, defined as hyperuricemia and a history or presence of gout according to ACR criteria and baseline sUA levels ≥ 8 mg/dL, ≤12 mg/dL were administered LC350189 (50, 100, and 200 mg) or placebo orally, once daily for 3 months, with a subset of 13 out of 156 participants enrolled in a febuxostat, 40mg – 80 mg QD, active control group.
During the study period, colchicine 0.6 mg (QD) was prescribed for prophylaxis of gout flares. The primary endpoint was the response rate achieving sUA < 5 mg/dL at month 3.
Topline results from the CLUE study are as follows:
The proportion of gout patients reaching sUA < 5 mg/dL at month 3 by study arms was 47% (16/34) at 50 mg, 45% (17/38) at 100 mg, 62% (23/37) at 200 mg LC350189, respectively, 23% (3/13) with Febuxostat and 3% (1/34) with placebo.
The proportion of patients achieving sUA < 6 mg/dL at month 3 as the secondary endpoint was 59%, 63%, 78% at 50, 100, and 200 mg of LC350189, respectively, 54% in the Febuxostat group, and 3% in the placebo group.
LC350189 showed good dose-dependent reduction in sUA levels lowering rapidly within 2 weeks, and sUA levels were well maintained throughout the study period.
LC350189 was well tolerated in gout patients at all dose levels compared to the placebo group. There was no notable difference in the overall incidence of TEAE (treatment-emergent adverse events) between the active and placebo groups.
“Many gout patients could benefit from medicines with improved efficacy and safety profiles from the current standard of care. As LC350189 demonstrated in the CLUE study, we can be confident that LC350189 will be a better treatment option for gout patients in the near future,” said Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea.
About LC350189:
LC350189 is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in the final product in purine metabolism, by inhibiting the activity of xanthine oxidase. It has a different structure from other xanthine oxidase inhibitors such as the purine analog xanthine oxidase inhibitor, allopurinol. LC350189 is under development as a 1st line treatment in the U.S. and has demonstrated sufficient efficacy for sUA lowering and a good safety profile in a Phase 2 study.
About Gout:
Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia, which is variably defined as a serum urate level greater than either 6.8 or 7.0mg/dL. Tissue deposition of monosodium urate monohydrate crystals in supersaturated extracellular fluids of the joint, and certain other sites, mediates most of the clinical and pathologic features of gout. Typically, the disease initially presents as acute episodic arthritis. Gout also can manifest as chronic arthritis of one or more joints. Diagnosis of chronic gout should be considered in patients when more that 4 of following criteria are met: 1. attack of acute arthritis, 2. mono or oligoarthritis attacks, 3. rapid onset of pain and swelling, 4. podagra, 5. erythema, 6. unilateral tarsitis, 7. possible tophi, and/or 8. Hyperuricemia
Sources:
Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46.
Peláez-Ballestas I, et al. Diagnosis of chronic gout: evaluating the American college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment. J Rheumatol. 2010 Aug 1;37(8):1743-8.
About LG Chem Life Sciences:
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make a global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue asset-centric global collaborations including strategic investments.
innovation.lgchem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005263/en/
Contacts
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
Permalink : https://www.aetoswire.com/news/lg-chem-announces-topline-results-of-lc350189-from-the-phase-2-study-clue-study-promising-to-be-a-new-treatment-alternative-with-improved-efficacy-and-safety-profiles-for-chronic-gout-patients/en
Friday, July 2, 2021
LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
Thursday, July 1, 2021
Holicity Board Urges Stockholders to Vote TODAY in Support of Business Combination with Astra Space, Inc.
Holicity Special Meeting of Stockholders Scheduled to Commence June 30 at 8:00 a.m. ET
NEW YORK-Thursday 1 July 2021 [ AETOS Wire ]
(BUSINESS WIRE) -- Holicity Inc. (“Holicity” or the “Company”) (NASDAQ: HOL) issued the following statement to Holicity stockholders reiterating the Holicity Board of Directors’ recommendation in favor of the transaction with Astra Space, Inc. (“Astra”), pursuant to the Business Combination Agreement, dated February 2, 2021, by and between Astra, Holicity and Holicity Merger Sub Inc, a wholly-owned subsidiary of Holicity (the “Business Combination Agreement”).
Holicity Inc. is scheduled to hold a Special Meeting of Stockholders at 8:00 AM ET on June 30, 2021 to approve a business combination with Astra Space, Inc. We are asking stockholders that held shares of Holicity Inc. on May 24, 2021 (the record date) to cast their vote so that their shares are represented at the June 30 meeting. Your vote is extremely important; the closing of the business combination cannot happen without your support. The deadline for voting online is today, June 29th at 11:59 pm ET.
Stockholder interest has been strong, however if not enough shares are voted by the deadline, then the Special Meeting could fail to reach a quorum and cause the business combination to be delayed. A larger percentage of retail investors poses a unique challenge for us to reach stockholders who may not be accustomed to the process of voting in special meetings. “Retail investors may not always realize the importance that voting even a small number of shares can have in successfully completing a merger like this,” said Randy Russell, Chief Investment Officer of Holicity. “We believe this transaction is in the best interest of our stockholders, and it is critical that everyone who has the opportunity to vote do so."
If any stockholder wishes to take part in this process, they should contact their brokers to learn how to cast their vote, or visit www.holicity.inc.
Any stockholder can also contact Morrow Sodali LLC, Holicity’s proxy solicitor, by telephone at (800) 662-5200 or by email at HOL.info@investor.morrowsodali.com for help with voting or if they have any questions.
We thank you for your continued support of Holicity.
Important Information About the Business Combination and Where to Find It
In connection with the proposed Business Combination, the Company publicly filed with the SEC a registration statement on Form S-4 (the “Registration Statement”) on May 3, 2021 (Registration No. 333- 255703), which includes a proxy statement/prospectus, and certain other related documents, which will be both the proxy statement to be distributed to holders of shares of the Company’s common stock in connection with the Company’s solicitation of proxies for the vote by the Company’s stockholders with respect to the Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of the Company to be issued in the Business Combination. The registration statement became effective on June 4, 2021. The Company’s stockholders and other interested persons are advised to read the proxy statement/prospectus included in the Registration Statement and the amendments thereto, as these materials will contain important information about the parties to the Business Combination Agreement, the Company and the Business Combination. The definitive proxy statement/prospectus was mailed on or about June 7, 2021 to stockholders of the Company as of a record date established for voting on the Business Combination and other matters as may be described in the Registration Statement. Stockholders are able to obtain copies of the proxy statement/prospectus and other documents filed with the SEC that will be incorporated by reference in the proxy statement/prospectus, without charge, at the SEC’s web site at sec.report, or by directing a request to: Holicity Inc., 2300 Carillon Point, Kirkland, WA 98033, Attention: Craig McCaw, Chief Executive Officer, (425) 278-7100.
Participants in the Solicitation
The Company and its directors and executive officers may be deemed participants in the solicitation of proxies from the Company’s stockholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in the Company is contained in the Company’s registration statement on Form S-1, which was initially filed with the SEC on July 17, 2020, and is available free of charge at the SEC’s web site at sec.gov, or by directing a request to Holicity Inc., 2300 Carillon Point, Kirkland, WA 98033, Attention: Secretary, (425) 278-7100. Additional information regarding the interests of such participants is contained in the Registration Statement.
Astra and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination is contained in the Registration Statement.
Forward-Looking Statements
This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s and Astra’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s and Astra’s expectations with respect to future performance and anticipated financial impacts of the Business Combination and the Mergers, the satisfaction of the closing conditions to the Business Combination and the Mergers and the timing of the completion of the Business Combination and the Mergers. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company’s and Astra’s control and are difficult to predict. The Company and Astra caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company and Astra do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005877/en/
Contacts
Astra
Media
kati@astra.com
Investors
investors@astra.com
Carolyn Bass
Market Street Partners
cbass@marketstreetpartners.com
Holicity
Media
Todd Wolfenbarger
todd@summitslc.com
+1(801) 244-9600
Permalink : https://www.aetoswire.com/news/holicity-board-urges-stockholders-to-vote-today-in-support-of-business-combination-with-astra-space-inc/en
Inclusive Fintech 50 launches 2021 competition to recognize early-stage fintechs driving innovation in an era of uncertainty
An independent panel of leading fintech experts will select 50 innovative inclusive fintech startups helping communities rebuild from the pandemic
WASHINGTON-Wednesday 30 June 2021 [ AETOS Wire ]
(BUSINESS WIRE) -- The Center for Financial Inclusion (CFI) has launched the third year of Inclusive Fintech 50 (IF50), a competition to recognize the most promising inclusive fintech startups pushing the frontiers of innovation. This year, the competition seeks to recognize early-stage fintechs that are helping low-income customers and micro- and small enterprises not just respond to the pandemic, but rebound, rebuild, and recover after the past year’s devastation.
IF50 is sponsored by Visa, MetLife Foundation, and Jersey Overseas Aid & Comic Relief, with support from Accion and IFC. In its first two years, IF50 attracted applications from over 700 startups across 162 countries, cumulatively reaching almost 175 million customers. Each year, an independent judging panel of global fintech experts reviews the applicants to select 50 winners based on four criteria: inclusivity, innovation, scale potential, and traction.
Participation in the competition provides startups with visibility and credibility among investors as well as media and partnership exposure; 19 winners from the 2019 cohort have since raised a collective $182.5 million in investment. In addition, this year’s winners will be featured in early November during Financial Inclusion Week, an annual virtual event organized by CFI for the inclusive finance community to discuss the latest developments and key issues facing the sector. Winners will also be featured in this year’s research findings and media coverage. For example, several publications from the past two years prominently featured IF50 winners.
For the 2021 competition, new benefits to IF50 winners include access to Practical Business Skills, a global digital platform created by Visa to deliver free educational resources to help small and micro business owners make confident, informed decisions to grow their businesses. Winners will be able to customize and co-brand this turn-key solution to support the local recovery efforts of the small and micro businesses they serve. Eligible winners will automatically pre-qualify for Visa Fintech Fast Track, a program that aims to speed up the process of integrating with Visa and its ecosystem partners and helps fintechs enhance and introduce new and innovative payment experiences. These tools, together with the networking and platform that IF50 provides, serve as an invaluable platform for startups at the earliest stages of their journey.
As the COVID pandemic continues to rage in many parts of the world, fintech startups and services have proven to be an invaluable lifeline for vulnerable people, facilitating remittances, digital payments, and payments associated with government safety nets. Higher rates of fintech acceptance present new opportunities for startups to go beyond traditional offerings to deliver valuable financial services that will ensure the financial health and resilience of underserved people.
Expert judges include a diverse group of independent fintech experts, investors, and founders, including:
Nejoud Al Mulaik, Director, Fintech Saudi
Tarek Assad, Managing Partner, Algebra Ventures
Sarah Austrin-Willis, Senior Director, Financial Solutions Lab, Financial Health Network
Ginger Baker, Head of Financial Access, Plaid
Anne-Marie Chidzero, Chief Investment Officer, FSD Africa Investments
Bernhard Eikenberg, Managing Partner, Emerging Markets, Community Investment Management
Brad Jones, CEO, Wave Money
Buhle Goslar, Africa CEO, Jumo
Jojo Malolos, CEO, JG Digital Equity Ventures and Data Analytics Ventures
Kunal Upadhyay, Advisor, ADB Ventures
Shwetank Verma, Co-Founder and General Partner, Leo Capital
Gabriela Zapata Alvarez, Independent Consultant (Financial Inclusion)
The application window opens today, and interested startups are encouraged to apply by July 23 via the IF50 website.
Key quotes:
Managing Director of the Center for Financial Inclusion, Mayada El-Zoghbi, highlighted the timeliness of the theme noting, “As the world continues to wrestle with the challenges presented by the pandemic, fintechs can play an important role in helping those most impacted move towards recovery. For example, by supporting micro- and small enterprises, which have been devastated by the pandemic but will be ground zero for eventual economic recoveries across the developing world. As difficult as this crisis has been, it has prompted a surge in fintech innovation and an openness to new ideas, the benefits of which could be applied to other challenges beyond the pandemic. We need to be intentional about how we can use this as a springboard for making advances elsewhere, such as with women’s financial inclusion, the responsible use of data, and in navigating the impacts of climate change.”
Beth Hurvitz, Global Head of Social Impact, Visa Inc., noted, “Digital payments are an onramp for financial inclusion, helping people and businesses meet their needs and stay afloat in the current context. Fintechs are key to enhancing access and the benefits of digital adoption for the underserved. Visa is committed to work with the payments ecosystem on initiatives such as Inclusive Fintech 50, to support SMB owners to become digitally enabled and rebuild stronger, more competitive and resilient businesses for the recovery of our communities.”
Krishna Thacker, Director, MetLife Foundation, noted, “At MetLife Foundation, we recognize the ability of tech to reach low-income people further and faster, but we’re also focused on engaging the customer and changing their financial outcomes. Through Inclusive Fintech 50, we want to identify, recognize and support organizations that are going beyond inclusion to build resilience and financial health for low-income customers – a need highlighted by the pandemic.”
About IF50
Inclusive Fintech 50 identifies promising early-stage fintechs driving financial inclusion around the globe through a competitive process led by an independent panel of judges from venture capital, technology, and financial services. Applicants are assessed on the degree to which their target market includes underserved people or businesses, and whether their innovation offers a new value proposition, shows early-stage traction, and can have a noticeable impact on the more than 3 billion financially underserved people globally. Inclusive Fintech 50 is sponsored by Visa, MetLife Foundation, and Jersey Overseas Aid & Comic Relief, with support from Accion and IFC. The initiative is managed by the Center for Financial Inclusion (CFI). Learn more at www.inclusivefintech50.com.
About The Center for Financial Inclusion
The Center for Financial Inclusion (CFI) works to advance inclusive financial services for the billions of people who currently lack the financial tools needed to improve their lives and prosper. We leverage partnerships to conduct rigorous research and test promising solutions, and then advocate for evidence-based change. CFI was founded by Accion in 2008 to serve as an independent think tank on inclusive finance.
About Visa
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information visit About Visa and @VisaNews.
About MetLife Foundation
At MetLife Foundation, we are committed to expanding opportunities for low- and moderate-income people around the world. We partner with nonprofit organizations and social enterprises to create financial health solutions and build stronger communities, while engaging MetLife employee volunteers to help drive impact. MetLife Foundation was established in 1976 to continue MetLife’s long tradition of corporate contributions and community involvement. From its founding through the end of 2019, MetLife Foundation provided more than $900 million in grants and $87 million in program-related investments to make a positive impact in the communities where MetLife operates. Our financial health work has reached more than 17.3 million low- and moderate-income individuals in 42 countries. To learn more about MetLife Foundation, visit metlife.org.
About Jersey Overseas Aid & Comic Relief
In 2018, Comic Relief and Jersey Overseas Aid announced a four-year £8 million partnership called ‘Branching Out: Financial Inclusion at the Margins’ to improve access to affordable financial services for those at the margins of society in Sierra Leone, Rwanda and Zambia. Comic Relief and Jersey Overseas Aid believe that one of the best ways to do this is by transferring knowledge to build responsible and inclusive financial systems, incubating FinTech, and focusing on service delivery to increase bottom-of-the-pyramid access to financial services including bank accounts, savings, insurance and credit, providing low-income households with the means to plan for the future as well as unexpected events. The partnership grants support a diverse set of organisations, made up of international and local NGOs, with each grantee delivering programmes designed to meet different community and national needs in addressing financial inclusion.
About Accion
Accion is a global nonprofit committed to creating a financially inclusive world, with a pioneering legacy in microfinance and fintech impact investing. We catalyze financial service providers to deliver high-quality, affordable solutions at scale for the three billion people who are left out of — or poorly served by — the financial sector. For 60 years, Accion has helped tens of millions of people through our work with more than 160 partners in 55 countries. More at http://www.accion.org.
About IFC
IFC—a member of the World Bank Group—is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2020, we invested $22 billion in private companies and financial institutions in developing countries, leveraging the power of the private sector to end extreme poverty and boost shared prosperity. For more information, visit www.ifc.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005166/en/
Contacts
Lauren Braniff, Vice President, Strategy and Communications
Center for Financial Inclusion: lbraniff@accion.org
Permalink : https://www.aetoswire.com/news/inclusive-fintech-50-launches-2021-competition-to-recognize-early-stage-fintechs-driving-innovation-in-an-era-of-uncertainty/en
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
OSAKA, Japan-Wednesday 30 June 2021 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: https://www.takeda.com/investors/sec-filings/.
In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at takeda.ir.contact@takeda.com.
Additionally, Takeda also published today its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. It can be accessed on Takeda’s website at: https://air.takeda.com.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)
is a global, values-based, R&D-driven biopharmaceutical leader
headquartered in Japan, committed to discover and deliver
life-transforming treatments, guided by our commitment to patients, our
people and the planet. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience,
and Gastroenterology (GI). We also make targeted R&D investments in
Plasma-Derived Therapies and Vaccines. We are focusing on developing
highly innovative medicines that contribute to making a difference in
people’s lives by advancing the frontier of new treatment options and
leveraging our enhanced collaborative R&D engine and capabilities to
create a robust, modality-diverse pipeline. Our employees are committed
to improving quality of life for patients and to working with our
partners in health care in approximately 80 countries and regions. For
more information, visit https://www.takeda.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005633/en/
Contacts
Media:
Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414
Media Outside Japan
Christina Beckerman
christina.beckerman@takeda.com
+1 908-581-4133
Andersen Global Initiates Expansion Into the Norwegian Market
SAN FRANCISCO-Tuesday 29 June 2021 [ AETOS Wire ]
(BUSINESS WIRE) -- Andersen Global enters Norway through a Collaboration Agreement with law firm Brækhus, adding breadth to its footprint in Northern Europe as the organization continues its expansion in key markets throughout the region.
Led by Managing Partner Frank C. Aase, Brækhus is a full-service law firm based in Oslo. Operating with 27 Partners and over 70 professionals, the firm’s capabilities include corporate, commercial, M&A, banking and finance, tax advisory, structuring and compliance, litigation, real estate, energy, construction, private client services, employment law, technology, e-commerce and intellectual property.
“Through transparency and uncompromisingly high professional standards, we look to form long-lasting relationships that create an added value for our clients,” Frank said. “A collaboration agreement with Andersen Global fits well with our international strategy and perfectly complements our existing international legal and tax liaisons. Arthur Andersen alumnus and tax Partner Nils Eriksen will assist us as we collaborate with the member firms and collaborating firms of Andersen Global. Our firm’s cultural synergy with the organization reinforces our vision and positions us to seamlessly deliver best-in-class and innovative solutions globally.”
“Brækhus is highly regarded for their experience, expertise and ability to provide clients with independent, integrated solutions,” said Andersen Global Chairman and Andersen CEO Mark Vorsatz. “Norway is a very important market in our expansion strategy, and our inimitable chemistry with Nils, Frank and their team provides an outstanding complement to our existing platform in the region.”
Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 7,000 professionals worldwide and a presence in over 277 locations through its member firms and collaborating firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005411/en/
Contacts
Megan Tsuei
Andersen Global
415-764-2700
Permalink : https://www.aetoswire.com/news/andersen-global-initiates-expansion-into-the-norwegian-market/en
Leading Brazilian Chemical Distributor Switches to Rimini Street Support for SAP S/4HANA
quantiQ leverages Rimini Street to help maximize its SAP investment and use newly generated savings to fund innovation and process efficiencies
LAS VEGAS -Wednesday 30 June 2021 [ AETOS Wire ]
(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that quantiQ, a leading Brazilian distributor of chemical products based in São Paulo, has switched to Rimini Street Support for SAP S/4HANA. By switching to Rimini Street, quantiQ saved 75% in total support costs compared to what the company was spending under the vendor’s support. The company plans to reallocate its liberated funds and resources to invest in innovation and process efficiencies across the organization, including a new customer portal, e-commerce initiatives and implementing intelligent automation and RFID capabilities. These initiatives are considered essential projects to maintain its competitive edge and better serve its customers and partners.
Rimini Street Support Improves Workflow and Operational Efficiencies
A subsidiary of GTM Holdings S.A. Advent International (GTM), quantiQ is a distributor that develops, tests, stores and handles chemical products. GTM operates in Latin America with more than 1,000 employees across 11 offices, with new offices in the United States and China on the horizon. When GTM acquired quantiQ in 2017, there were already demands for efficiency and plans to restructure quantiQ’s business processes. A part of that process was deploying SAP S/4HANA.
In early 2020, quantiQ’s strategy was to create a new hybrid technology platform. Due to the disruption caused by the pandemic, it needed to accelerate this strategy and quickly implement digital initiatives. In addition, quantiQ wanted to increase its operational efficiency and get the most out of its ERP investment. quantiQ chose Rimini Street Support for SAP S/4HANA because of the Company’s expertise in helping clients both maximize the value derived from their ERP systems and strategically plan and execute a business-driven IT roadmap. By switching to Rimini Street Support, quantiQ was able to save significant costs related to its vendor support enabling it to invest in critical digital projects. They also now receive a higher quality of support, including support for all of their customizations and help with their integration requirements.
“We want to establish ourselves as a digital transformation leader in the chemical product distribution industry,” stated Jessé Gusmão, chief information officer, quantiQ. “Our partnership with Rimini Street will leverage our capacity to be more strategic and oriented to our business and also to invest in new initiatives so that we can improve the value and quality of services provided and ensure that customers see our business as reliable and innovative.”
Expert Support for SAP S/4HANA
Rimini Street Support for SAP S/4HANA helps stabilize and optimize operations on current releases, avoids the churn of ongoing upgrades and updates and focuses resources on innovation and process efficiency on the foundation of S/4HANA. Rimini Street delivers full support for SAP S/4HANA, including support for custom code and tax, legal and regulatory updates. The Company’s expert engineers also provide guidance and advisory services to quantiQ’s internal teams around strategic application roadmap planning and specialized interoperability solutions.
“Rimini Street Support for S/4HANA delighted us due to its differentiated support model. The Company’s 10-minute response SLA brings our IT department peace of mind knowing that our support partner is ultra-responsive and has highly experienced engineers handling any issues. We can focus on business initiatives with more efficiency and don’t waste any more time having to manage IT support requests,” continued Gusmão.
“Whether SAP licensees are currently running S/4HANA, considering migrating to S/4HANA in the future or unsure if S/4HANA is part of their plans, Rimini Street’s award-winning support can help them maximize their investments and help put them back in control of their IT roadmap,” said Edenize Maron, General Manager, Latin America, Rimini Street. “Rimini Street is honored to help enable quantiQ to reinforce its position as an innovation leader in Latin America and increase its investments focused on the demands of its customers. Like quantiQ, all Rimini Street clients receive strategic and high-quality ERP support designed to optimize its resources and help contribute to its growth in the face of constant market challenges.”
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,000 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and operational and financial impacts on our business of the COVID-19 pandemic and related economic impact, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the terms and impact of our outstanding 13.00% Series A Preferred Stock; our ability to maintain an effective system of internal control over financial reporting, and our ability to remediate identified material weaknesses in our internal controls, including in relation to the accounting treatment of our warrants; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on May 10, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005305/en/
Contacts
Michelle McGlocklin
Rimini Street, Inc.
+1 925 523-8414
mmcglocklin@riministreet.com
Permalink : https://www.aetoswire.com/news/leading-brazilian-chemical-distributor-switches-to-rimini-street-support-for-sap-s-4hana/en
Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan
TOKYO -Wednesday 30 June 2021 [ AETOS Wire ]
NDA filed in Japan ahead of anywhere else in the world
New anti-cancer drug with a novel mechanism of action
Darinaparsin is designated Orphan Drug in the US and EU as a treatment of peripheral T-cell lymphoma (PTCL)
(BUSINESS WIRE)-- Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) today announced submission of a New Drug Application (NDA) for its new anti-cancer drug darinaparsin (generic name, development code: SP-02) as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare (MHLW). Based on positive results of R&D on darinaparsin, centered primarily on the results of the Asian Multinational Phase 2 Study (study results released in June 2020), Solasia filed an NDA for the drug with the regulatory authority in Japan ahead of anywhere else in the world.
Solasia expects to obtain regulatory approval in 2022 and to also launch in the same year. If approved and launched, darinaparsin would be the third drug Solasia successfully developed and brought to market since its founding and is expected to contribute to the treatment of PTCL.
Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:
“No standard treatment has been established for relapsed or refractory PTCL as of yet. I firmly believe that darinaparsin, with its novel mechanism of action that differs from those of already approved drugs, will contribute to patients and healthcare providers at clinical sites as a new treatment option for relapsed or refractory PTCL. Since founding, Solasia has conducted R&D on five pipeline drugs. Of the five, we have successfully developed and brought to market two drugs, i.e., began providing them to patients, and today, we submitted an NDA for our first anti-cancer drug. Under our mission to provide patients with ‘Better Medicine for a Brighter Tomorrow’, we will continue aiming to contribute to patients’ treatment and enhanced quality of life. ”
About darinaparsin (SP-02)
Darinaparsin, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. Darinaparsin is believed to exert anticancer effect by inducing cell cycle arrest and apoptosis. Darinaparsin has been granted orphan drug designation in the US and EU.
For more information, please visit at https://solasia.co.jp/en/pipeline/sp-02.html
About Asian Multinational Phase 2 Study
The Asian Multinational Phase 2 Study was a multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in patients with relapsed or refractory PTCL conducted in Japan, Korea, Taiwan, and Hong Kong. (CT.gov Identifier: NCT02653976).
Solasia plans to present the results of the study at an international academic conference to be held in the near future.
About peripheral T-cell lymphoma (PTCL)
Please visit at https://solasia.co.jp/en/pipeline/sp-02.html
About Solasia
Please visit at https://solasia.co.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005395/en/
Contacts
Solasia Pharma K.K.
Rie Toyoda, Public Relations and Investor Relations,
Tel. +81 3 5843 8049
info@solasia.co.jp
Permalink : https://www.aetoswire.com/news/solasia-announces-submission-of-new-drug-application-for-anti-cancer-drug-darinaparsin-for-peripheral-t-cell-lymphoma-in-japan/en